ENDPOINTS

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive $1.5 billion upfront from Bristol Myers Squibb to co-develop and ...

Jun 2, 2025 - 11:54
 0
Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus
BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive $1.5 billion upfront from Bristol Myers Squibb to co-develop and ...
Read More

Tags:

Previous Article

First Vaccine for Gonorrhea Rolls Out, Measles Outbreak in Texas Slows, and Mega...

Next Article

Warplanes Pacific & Border Bots Are June's Horizon+ Monthly Games On Quest

Related Posts

FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale

FDA clears in vivo blood stem cell editing trial; Abeon...

May 12, 2025  0

Remote patient monitoring is ready for its moment

Remote patient monitoring is ready for its moment

Jun 3, 2025  0

Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Galapagos backpedals on separation plans, CEO Paul Stof...

May 13, 2025  0